BioTuesdays

Category - Markets

OPKO Health
Markets

OPKO completes acquisition of Transition Therapeutics

OPKO Health (NASDAQ:OPK) has completed the acquisition of Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) by way of a plan of arrangement. Under the transaction, shareholders of Transition will receive about 6.4 million...

August 31, 2016
Neuralstem
Markets

Roth starts Neuralstem at buy

Roth Capital Partners launched coverage of Neuralstem (NASDAQ:CUR) with a “buy” rating and price target of $1.20. The stock closed at 25 cents on Friday. Analyst Joseph Pantginis writes that Neuralstem has undergone a...

August 29, 2016
Actinium
Markets

Roth starts Actinium Pharma at buy

Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday. “We believe it is an opportune time to explore the...

August 25, 2016
Tactile Systems Technology
Markets

Analysts start Tactile Systems at buy, outperform

Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively. Tactile makes pneumatic...

August 22, 2016
Leerink Logo
Markets

Leerink upgrades Cardiovascular Systems

Leerink Partners upgraded Cardiovascular Systems (NASDAQ:CSII) to “outperform” and raised its price target to $30 from $23. The stock closed at $22.60 on Friday. “Now with two solid quarters in a row of stable-to...

August 22, 2016
William Blair
Markets

WB starts 4 chronic Hep B biotechs at outperform

William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier. “Curing chronic hepatitis B infections is the next frontier...

August 19, 2016
Leerink Logo
Markets

Leerink downgrades Mirna to market perform

Leerink Partners downgraded Mirna Therapeutics (NASDAQ:MIRN) to “market perform” from “outperform” and lowered its price target to $4 from $10, citing added uncertainties around the development path and safety profile...

August 17, 2016
OncoGenex
Markets

WB drops coverage of OncoGenex

William Blair dropped coverage of OncoGenex (NASDAQ:OGXI) after the company announced that the AFFINITY study did not meet the primary endpoint. The stock closed at 90 cents on Monday. “We note that AFFINITY is the key...

August 16, 2016
Profound Medical Logo
Markets

Profound Medical names Arun Menawat as CEO

Profound Medical (TSX-V:PRN) appointed Arun Menawat as its new CEO.  Steven Plymale, the company’s current CEO, will transition to President and COO. Dr. Menawat has been a member of Profound’s board since October 2014...

August 15, 2016
CymaBay
Markets

Roth ups CymaBay price target to $6

Roth Capital Partners raised its price target for CymaBay Therapeutics (NASDAQ:CBAY) to $6 from $4, citing a potential partnership for the company’s gout product. The stock closed at $1.79 on Thursday. “Following...

August 12, 2016